Charles Bradley

vp clinical development at BiPar Sciences - South San Francisco, California, United States

Charles Bradley's Colleagues at BiPar Sciences
Charles Bradley's Contact Details
HQ
Location
Company
BiPar Sciences
Charles Bradley's Company Details
BiPar Sciences logo, BiPar Sciences contact details

BiPar Sciences

South San Francisco, California, United States • 11 - 50 Employees
Biotechnology

BiPar Sciences is advancing the field of cancer therapy through the development of a novel class of tumor-selective drugs, called PARP inhibitors, designed to target multiple cancer types, including therapy-resistant and difficult-to-treat cancers. BiPar Sciences' lead product candidate, iniparib, the United States Adopted Name (USAN) for the investigational PARP1 inhibitor, BSI-201, targets PARP, or poly (ADP-ribose) polymerase, a key enzyme involved in DNA repair and cell proliferation. Iniparib significantly enhances the anti-tumor effects of chemotherapy and has shown promising safety and efficacy results in patients with solid tumors.Iniparib is being evaluated in multiple Phase 2 and Phase 3 clinical trials in advanced solid tumors, including triple-negative breast cancer. The company also has two additional compounds in pre-clinical development: BSI-401, a follow-on PARP inhibitor candidate being investigated as an oral therapy for pancreatic cancer, and BSI-302, a novel anti-tubulin therapy

Details about BiPar Sciences
Frequently Asked Questions about Charles Bradley
Charles Bradley currently works for BiPar Sciences.
Charles Bradley's role at BiPar Sciences is vp clinical development.
Charles Bradley's email address is ***@bipasciences.com. To view Charles Bradley's full email address, please signup to ConnectPlex.
Charles Bradley works in the Biotechnology industry.
Charles Bradley's colleagues at BiPar Sciences are Marilyn Enderson, Atul Dhir and others.
Charles Bradley's phone number is
See more information about Charles Bradley